atrasentan has been researched along with Hypertension, Renal in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Certíková Chábová, V; Červenka, L; Husková, Z; Kramer, HJ; Kujal, P; Skaroupková, P; Tesař, V; Vaněčková, I; Vaňourková, Z; Vernerová, Z | 1 |
| Polakowski, JS; Pollock, DM | 1 |
2 other study(ies) available for atrasentan and Hypertension, Renal
| Article | Year |
|---|---|
Effects of combined endothelin A receptor and renin-angiotensin system blockade on the course of end-organ damage in 5/6 nephrectomized Ren-2 hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Atrasentan; Disease Models, Animal; Drug Therapy, Combination; Endothelin A Receptor Antagonists; Hypertension, Renal; Indoles; Kidney; Losartan; Male; Nephrectomy; Pyrrolidines; Rats; Rats, Sprague-Dawley; Rats, Transgenic; Receptor, Angiotensin, Type 1; Receptor, Endothelin A; Renal Insufficiency, Chronic; Renin-Angiotensin System; Survival Analysis; Treatment Outcome | 2012 |
ETA receptor blockade prevents hypertension associated with exogenous endothelin-1 but not renal mass reduction in the rat.
Topics: Administration, Oral; Animals; Atrasentan; Blood Pressure; Disease Models, Animal; Endothelin Receptor Antagonists; Endothelin-1; Endothelins; Hypertension, Renal; Kidney; Kidney Failure, Chronic; Male; Nephrectomy; Protein Precursors; Proteinuria; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptor, Endothelin A | 1997 |